<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04221230</url>
  </required_header>
  <id_info>
    <org_study_id>K2-MDD-201</org_study_id>
    <nct_id>NCT04221230</nct_id>
  </id_info>
  <brief_title>Study in Major Depressive Disorder With BTRX-335140 vs Placebo</brief_title>
  <official_title>A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral BTRX-335140 Versus Placebo in Subjects With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BlackThorn Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BlackThorn Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A proof of concept (POC) study evaluating the impact of BTRX-335140 relative to placebo on
      symptoms of major depressive disorder (MDD) in adult subjects with MDD and symptoms of
      anhedonia and anxiety following 8 weeks of double-blind treatment as assessed by the HAMD-17
      Scale.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale (HAMD-17)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in baseline to Week 8 on the HAMD-17 score; Minimum 0, Maximum 52; Higher scores mean a worse outcome</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>BTRX-335140</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BTRX-335140</intervention_name>
    <description>active drug</description>
    <arm_group_label>BTRX-335140</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are adult men or women 25 to 65 years of age (inclusive) at informed consent, who
             provide informed consent by signing the appropriate ICFs

          -  Have a primary DSM-5 diagnosis of MDD, with prominent symptoms of anhedonia confirmed
             by Structured Clinical Interview for DSM Disorders, Clinical Trials Version (SCID-CT)

          -  Meet the algorithm-based clinical scale criteria

          -  Body mass index between 18 to 35 kg/m2

          -  Medically stable (in the opinion of the investigator and Sponsor/Sponsors delegate)
             based on medical history, vital signs, clinical laboratory tests, and 12-lead ECG
             performed at screening and baseline

          -  Agree to birth control

          -  Willing and able to give written informed consent to participate

          -  Able to understand and comply with instructions in English

          -  Are judged to be reliable and agree to keep all appointments for clinic visits, tests,
             and procedures, including venipuncture, and examinations required by the protocol

        Exclusion Criteria:

          -  Any current DSM-5 disorder other than MDD (including bipolar 1 &amp; 2, schizophrenia,
             personality disorder, attention deficit disorder/ attention deficit hyperactivity
             disorder [ADD/ADHD], bulimia nervosa, or PTSD). Subjects with comorbid GAD, social
             anxiety disorder (SAD) or panic disorder for whom MDD is considered the primary
             diagnosis are not excluded.

          -  Are actively suicidal (eg, any suicide attempts within the past 12 months or any
             current suicidal intent, including a plan) or are at serious suicidal risk, as
             assessed by the C-SSRS (score of &quot;YES&quot; on suicidal ideations item 4 or 5 or any
             suicide attempt item within 3 months prior to

          -  Have any significant history of substance or alcohol use disorder (lifetime) per DSM-5
             criteria

          -  Have signs of Cushing's disease, Addison's Disease, primary amenorrhea or other
             evidence of significant disorders of the hypothalamus-pituitary-adrenal (HPA) axis

          -  Have any other clinically significant medical or psychiatric condition or circumstance
             prior to randomization that, in the opinion of the investigator, or Sponsor could
             affect subject safety, preclude evaluation of response, interfere with the ability to
             comply with study procedures, or prohibit completion of the study

          -  Have had prior seizures (other than remote history of childhood febrile seizure) or
             other condition that would place the subject at increased

          -  Have a history of serious head injury (eg, skull fracture, cerebral contusion, or
             trauma resulting in prolonged unconsciousness), intracranial neoplasm, or hemorrhage

          -  Have had electroconvulsive treatment, transcranial magnetic stimulation or vagal nerve
             stimulation or treatment with ketamine or esketamine for MDD

          -  Have initiated psychotherapy (such as Cognitive Behavioral Therapy) or have had a
             change in psychotherapy, or other non-drug therapies (such as acupuncture or hypnosis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Tiller, MBChB</last_name>
    <role>Study Director</role>
    <affiliation>BlackThorn Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Gibbons</last_name>
    <phone>415-548-5471</phone>
    <email>michael.gibbons@BlackThornrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ProScience Research Group</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Bussel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haig Goenjian</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Behavioral Research Specialist, LLC</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesse Carr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Synergy San Diego</name>
      <address>
        <city>Lemon Grove</city>
        <state>California</state>
        <zip>91945</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Bari</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pacific Research Partners, LLC</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinna Gamez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Mark Joyce</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Suplicy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Riesenberg</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Altea Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jelena Kunovac</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Albuquerque Neuroscience, Inc.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Glen Michael Dempsey</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Finger Lakes Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Atkinson</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Otto Dueno</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Arnold</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grayline Research Center</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <zip>76309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benny Barnhart</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

